Whole Body Vibration
Whole body vibration delivers involuntary muscle contractions via the tonic vibration reflex plus osteocyte mechanotransduction. Fratini 2016 meta-analysis found Hedges g 0.09-0.21 BMD gains in postmenopausal women on LMHF platforms, with low back pain pooled SMD ~−0.6 across 14 RCTs.
Whole Body Vibration scored 7.2 / 10 (💪 Strong recommend) on the BioHarmony scale as a Device / Technology → Other Device.
What It Is
Type: Device (vibration platform).
Whole body vibration is a training and rehab modality in which the user stands, squats, or performs light movement on a platform that oscillates at a programmed frequency and amplitude. The mechanical stimulus transmits through the musculoskeletal system and triggers involuntary muscle contractions via the tonic vibration reflex (alpha motor neuron activation from Ia afferent feedback), plus direct mechanotransduction on osteocytes and osteoblasts, plus a pulsatile pressure gradient across lymphatic vessels, plus repeated proprioceptive perturbation that the nervous system must re-pattern around.
Terminology
- LMHF: Low-Magnitude High-Frequency. Vertical-oscillation WBV at 30-90 Hz and ≤0.5g, designed for osteocyte signaling and bone density. Marodyne and Juvent are the reference platforms.
- Pivotal / tri-planar: High-amplitude platform type operating at 5-30 Hz and 1-3g+, designed for muscle and performance via the tonic vibration reflex. Power Plate and Hypervibe are the reference platforms.
- Tonic vibration reflex: Neuromuscular reflex in which rapid muscle-spindle stretch drives alpha motor neuron firing, producing involuntary contraction cycles up to 40-50 per second.
- BMD: Bone mineral density, the gold-standard imaging surrogate for bone strength, measured by DXA at lumbar spine and hip.
- DXA: Dual-energy X-ray absorptiometry, the imaging method used to quantify BMD.
- Sclerostin: Protein expressed by osteocytes that inhibits bone formation; LMHF mechanical strain suppresses sclerostin, favoring bone anabolism.
- BFR: Blood Flow Restriction training, a technique using pneumatic cuffs at 40-50% arterial occlusion pressure to amplify motor unit recruitment at low loads.
- UPDRS-III: Unified Parkinson's Disease Rating Scale, Part III (motor examination). Minimal clinically important difference (MCID) is roughly 3.25 points.
- VIBES: Vibration to Improve Bone in Elderly Subjects, the 24-month LMHF RCT (n=710) published in Ann Intern Med 2011.
- ADGRE2: Adhesion G Protein-Coupled Receptor E2, the gene whose missense variant causes vibratory urticaria (Boyden 2016 NEJM).
- SMD: Standardized mean difference, meta-analytic effect size. |SMD| >0.8 large, 0.5-0.8 moderate, 0.2-0.5 small.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| LMHF: 30 Hz / 0.3g / 10-20 min daily; Pivotal: 35-40 Hz / 2-4 mm / 15-30 min, 3-5x/week | Pivotal 20-40 Hz, 1-3g, often paired with BFR cuffs at 40-50% AOP |
Protocols
LMHF Bone Protocol Clinical
- Dose
- 30 Hz, 0.3g, 10-20 min standing
- Frequency
- daily
- Duration
- 6-12+ months; BMD signal requires 12-24 months to reach significance
Marodyne LivMD or Juvent. Target population: postmenopausal osteopenic, frail elders, long-term bedrest recovery.
Pivotal Performance Protocol Clinical
- Dose
- 35-40 Hz, 2-4 mm amplitude, 15-30 min
- Frequency
- 3-5x per week
- Duration
- indefinite
Power Plate or Hypervibe. Static holds, dynamic squats, unilateral work, push-up variations.
Parkinson's Adjunct Protocol Clinical
- Dose
- 6-25 Hz, low amplitude, 5-10 min
- Frequency
- 2-3x per week
- Duration
- adjunct, ongoing
Start low, supervised with PT during initial weeks. Observe for freezing-of-gait response.
Lymphatic AM Protocol (WBV + BFR stack) Anecdotal
- Dose
- 20-30 Hz, low amplitude, 5-10 min on waking
- Frequency
- daily
- Duration
- indefinite
Light bouncing, ankle pumps, arm swings. Optional BFR cuffs at low pressure. Biohacker morning circulation stack.
Progressive Safety Ramp (all users) Mixed
- Dose
- Start at 50% recommended duration and lowest intensity
- Frequency
- advance 25% per session
- Duration
- first 4 sessions
Never maximum intensity in session one. Stop and investigate frequency stability if lumbar pain develops on a budget platform.
How this score is calculated →
Upside (2.33 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 3.5 | 0.875 | |
| Speed of Onset | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 4.0 | 0.600 | |
| Total | 3.325 |
Upside Rationale
Efficacy (3.0/5.0). Population-dependent: for the right populations, moderate to large effect sizes; for healthy young adults, small to null. Low back pain shows the strongest pooled effect (SMD ~−0.6 across ~14 RCTs, del Pozo-Cruz 2012). Fratini 2016 found Hedges g 0.09-0.21 BMD gains at lumbar spine and hip in LMHF postmenopausal cohorts, with Marin-Cascales 2018 confirming similar hip magnitude. Oliveira 2016 showed moderate strength and Timed Up and Go gains in frail/pre-frail elders. Marconi 2019 reported Parkinson's motor SMD 0.06-0.46 with UPDRS-III gains of 3-6 points (at or near MCID). Acute pivotal pre-exercise priming transiently potentiates vertical jump, sprint start, and 1RM squat by 2-8%.
Breadth of Benefits (4.0/5.0). Musculoskeletal strength, bone density, sarcopenia reversal, falls prevention, Parkinson's motor symptoms, CP gait in children, chronic low back pain, lymphatic drainage, proprioception, glucose tolerance in T2DM (small but replicated signal), acute performance priming, and recovery flushing. More systems than most single-modality devices.
Evidence Quality (3.5/5.0). Over 80 RCTs, roughly 25 meta-analyses across indications, including the landmark Annals of Internal Medicine 2011 1-year LMHF trial and the VIBES 24-month RCT (n=710, Slatkovska 2011). Two decades of Rubin lab mechanistic bone work at Stony Brook. FDA-cleared platforms (Juvent) and international regulatory recognition (Marodyne CE Class IIa). Main caveats: heterogeneous protocols, platform taxonomy routinely ignored in pooled analyses, and publication bias likely for the consumer-plate industry. Per v0.5 evidence-integrity rules, this earns a mild −0.3 penalty for industry-segment bias offset by strong academic-lab independence — net 3.5.
Speed of Onset (3.0/5.0). Strength and balance: 4-12 weeks. Low back pain: 4-8 weeks. Sarcopenia markers: 12-16 weeks. Parkinson's: often transient within a single session, durable effects at 4-12 weeks. BMD: 6-12 months minimum, often 12-24 months to reach statistical significance.
Durability (2.0/5.0). Detrains like any training stimulus. LMHF bone gains likely require continued stimulus for maintenance, analogous to how impact loading gains revert on detraining. This is a "keep using it" modality, not a one-and-done.
Bioindividuality Upside (4.0/5.0). Unusually wide strong-responder profile: postmenopausal osteopenic women, frail and sarcopenic elders, Parkinson's patients, CP children, chronic LBP sufferers, sedentary and deconditioned adults, travelers without gym access, and lifters using it as a warm-up or lymphatic finisher. Healthy young athletes see the smallest marginal benefit — the opposite of how consumer marketing positions the category.
Downside (0.71 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.8 | 0.540 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 3.5 | 0.175 | |
| Time/Effort Burden | 5% | 2.2 | 0.110 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.570 | |||
| Harm subtotal × 1.4 | 1.694 | |||
| Opportunity subtotal × 1.0 | 0.360 | |||
| Combined downside | 2.054 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.714 |
Downside Rationale
Safety Risk (1.8/5.0). Low when matched to platform, dose, and population. The VIBES 24-month RCT (n=710) documented zero attributable adverse events on LMHF protocols. Occupational WBV literature (ISO 2631 truck-driver data) is not applicable: those are continuous 8-hour daily seated exposures at unfavorable frequencies, while therapeutic WBV is 10-20 minutes standing at calibrated frequencies. The most credible real-world concern is frequency drift under load on budget consumer platforms, where a nominal 30 Hz can drift into 5 Hz lumbar-resonance bands and show up as lumbar pain in reviews. Absolute contraindications are pregnancy, active DVT, vibratory urticaria (ADGRE2 variant, Boyden 2016 NEJM), and acute fracture. Relative: pacemaker/ICD, severe osteoporosis with compression history, recent lumbar disc surgery, retinal detachment. The v0.5 catastrophic floor is not triggered: no intrinsic life-threatening AE at therapeutic dose.
Side Effect Profile (1.8/5.0). The most common AE is cutaneous itch and erythema from vasodilation, documented at 22% pooled prevalence (Mueller 2019, Exp Dermatol). Strongly platform-dependent: side-alternating (teeter) platforms produced 31.4% incidence, tri-planar 0%. Usually resolves within days of exposure cessation. Otherwise minor muscle soreness, occasional transient dizziness at session start, and little else in the therapeutic-dose window. No systemic or neuroendocrine side effects documented.
Financial Cost (3.5/5.0). Power Plate Move and comparable tri-planar home units run $3,000-6,000. Marodyne LivMD runs $3,000-4,000. Juvent sits in a similar range. Budget Amazon platforms at $200-600 exist but are not equivalent devices (frequency drift above). Scored at the accessible-but-legitimate channel per v0.5 cost rules — the cheap plates fail the tissue-stability quality bar, so they do not qualify as the accessible-legitimate channel for this category. Mid-to-high cost for a home device, though a home unit replaces years of studio visits.
Time/Effort Burden (2.2/5.0). 10-20 minutes per day for LMHF bone protocols. 15-30 minutes per session 3-5 times per week for pivotal performance protocols. Zero travel if home-owned. Integrates into existing workouts as warm-up, finisher, or lymphatic flush. Low compliance friction compared to hour-long cardio or structured gym programming.
Opportunity Cost (1.5/5.0). Stackable with almost everything. Lifters run BFR on the plate. Travelers use it instead of a gym. Parkinson's patients add it to medication and PT. It does not replace progressive overload, running, or zone 2 cardio, but complements all of them without eating into training volume. Per v0.5 audience-vs-indication rules, scored for the indicated population (elders, postmenopausal women, PD patients, rehab populations); for healthy young adults chasing hypertrophy, opportunity cost is higher because the marginal benefit shrinks — that trade-off is captured in the Verdict, not the dimension score.
Dependency/Withdrawal (1.0/5.0). None. No neuroendocrine adaptation, no biological dependency, no withdrawal syndrome. Per v0.5 dependency-vs-addiction framework, this sits at the substrate-class / training-stimulus floor: stop using it, detrain normally over weeks.
Reversibility (1.0/5.0). Fully reversible. Training stimulus only. No implants, no pharmacology, no lasting physiological changes beyond ordinary detraining.
Verdict
✅ Best for: Postmenopausal or osteopenic women using LMHF daily for bone density (strongest BMD evidence base, Fratini 2016 + VIBES). Frail or sarcopenic elders for strength, balance, and falls prevention (Oliveira 2016). Parkinson's patients as a motor-symptom adjunct (Marconi 2019, UPDRS-III 3-6 point gains). CP children for gait and spasticity under supervised pediatric PT. Chronic low back pain sufferers who have plateaued on conventional PT (SMD ~−0.6). Lifters pairing pivotal WBV with BFR as a warm-up or recovery block. Lymphatic drainage and morning circulation protocols. Travelers and remote workers needing minimum-effective strength and proprioception without a gym. Anyone over 60 as general sarcopenia insurance.
❌ Avoid if: Pregnant (absolute). Active deep vein thrombosis (absolute). Confirmed vibratory urticaria / ADGRE2 variant (absolute). Pacemaker or ICD (consult cardiology before any pivotal use). Acute fracture, recent lumbar disc surgery, or unstable lumbar spine, especially for pivotal high-magnitude platforms. Retinal detachment or high-myopia retinal risk on a high-magnitude pivotal platform. Tempted by a $300 Amazon plate and planning to use it daily for bone — frequency drift is not hypothetical, and the consumer-tier plates are not equivalent to clinical-tier LMHF or pivotal devices.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Geriatric / Aging Population | 8.0 | Strongest-responder population. Oliveira 2016 meta: improved leg extensor strength and Timed Up and Go in frail/pre-frail. Sarcopenia and falls prevention cornerstone. |
| 💪 Bone / Joint Health | 7.5 | LMHF: Fratini 2016 meta Hedges g 0.09-0.21 BMD gain in postmenopausal women. Marin-Cascales 2018 confirms hip BMD. VIBES 24-mo n=710 anchors long-term data. |
| 💪 Lymphatic / Drainage | 7.5 | Rhythmic gravitational loading drives lymph through the thoracic duct. Mechanistic rationale strong; lymphatic system has no intrinsic pump beyond breathing and skeletal muscle. |
| 💪 Chronic Pain Management | 7.5 | Chronic low back pain: pooled SMD ~−0.6 on pain intensity across ~14 RCTs. One of the better-supported indications. |
| 💪 Healthspan | 7.0 | Falls prevention and sarcopenia reversal in elderly directly extend healthspan. Oliveira 2016 meta on frail/pre-frail populations. |
| 💪 Neuroprotection | 7.0 | Marconi 2019 Parkinson's meta SMD 0.06-0.46 on motor outcomes; UPDRS-III 3-6 point improvements near MCID. |
| 💪 Pediatric Use | 7.0 | Cerebral palsy gait and spasticity benefits in children under supervised pediatric PT. Not a general pediatric recommendation. |
| 💪 Recovery / Repair | 7.0 | Biohacker community and athlete reports; pair with BFR for post-training flushing. Mechanistic circulation support. |
| 💪 Injury Recovery | 7.0 | Post-surgical rehab (non-spinal) and proprioceptive ankle rehab well-established in PT settings. |
| 💪 Flexibility / Mobility | 7.0 | Balance and postural training benefits; Berg Balance Scale and Timed Up and Go consistently improve in elders. |
| 👍 Longevity / Lifespan | 6.5 | Indirect via sarcopenia prevention and falls reduction in aging; no direct lifespan RCTs. |
| 👍 Reaction Time / Coordination | 6.5 | Acute performance priming: 20-60 sec pre-exercise transiently improves jump, sprint start, 1RM by 2-8%. |
| 👍 Strength / Power | 6.5 | As adjunct to lifting: useful. Acute potentiation of vertical jump, sprint, 1RM by 2-8%. Not durable as stand-alone strength modality. |
| 👍 Metabolic Health | 6.0 | Small but replicated glucose tolerance improvement in T2DM populations. |
| 👍 Blood Sugar / Glycemic Control | 6.0 | Replicated signal for improved glycemic control in T2DM; modest effect size. |
| ⚖️ Anti-Inflammatory | 5.5 | Acute inflammatory response like any resistance exercise; chronic effects likely mild anti-inflammatory via muscle/endothelial adaptation. |
| ⚖️ Mitochondrial | 5.5 | Muscle mitochondrial biogenesis via exercise stimulus; indirect. |
| ⚖️ Energy / Fatigue | 5.5 | Subjective energy lift post-session in many users; indirect via circulation and muscular adaptation. |
| ⚖️ Cardiovascular | 5.5 | Acute heart rate and blood pressure response comparable to light cardio; no hard CV endpoints. |
| ⚖️ Neuroplasticity | 5.5 | Proprioceptive re-patterning drives cortical remapping in rehab populations; mechanistic. |
| ⚖️ Nerve Regeneration | 5.5 | Diabetic neuropathy small-scale studies show symptom relief; not regeneration per se. |
| ⚖️ Mood / Emotional Regulation | 5.5 | Exercise-mediated mood lift; not WBV-specific. |
| ⚖️ Stress / Resilience | 5.5 | Exercise-mediated HPA adaptation; indirect. |
| ⚖️ Muscle Growth / Hypertrophy | 5.5 | Hypertrophy as stand-alone is modest; as BFR-paired warm-up, meaningful. Not a primary hypertrophy tool. |
| ⚖️ Immune Function | 5.5 | Exercise-mediated immune modulation; indirect. |
| ⚖️ Acute Pain Relief | 5.5 | Acute circulation support for muscle soreness; not an analgesic. |
| ⚖️ Body Composition / Fat Loss | 5.0 | Minimal fat loss signal as stand-alone; favors lean-mass preservation in elderly. |
| ⚖️ Anxiety | 5.0 | No direct evidence. |
| ⚖️ Depression | 5.0 | No direct evidence. |
| ⚖️ HRV / Vagal Tone / Autonomic Balance | 5.0 | No direct HRV evidence; indirect via exercise adaptation. |
| ⚖️ Hormonal / Endocrine | 5.0 | Acute GH/testosterone bumps like resistance exercise; no durable hormonal signal. |
| ⚖️ Wound Healing | 5.0 | Indirect via circulation; no direct wound-healing RCTs. |
| ⚖️ Endurance / Cardio | 5.0 | Not a cardio substitute. Useful as warm-up. |
| ⚖️ VO2 Max | 5.0 | No direct VO2 improvement. |
| ⚖️ Respiratory | 5.0 | No direct respiratory evidence. |
| ○ Sleep Quality | 4.5 | No direct sleep RCTs; indirect via exercise-mediated sleep consolidation. |
| ○ Antioxidant / Oxidative Stress | 4.5 | Indirect via exercise-induced hormesis. |
| ○ Autophagy | 4.5 | Exercise-mediated autophagy via mTOR/AMPK; indirect. |
| ○ Stem Cell Support | 4.5 | Mechanical loading is a known osteoprogenitor stimulus; no direct stem-cell clinical data. |
| ○ Liver / Detoxification | 4.5 | No direct evidence. |
| ○ Cognition / Focus | 4.5 | No direct cognitive RCTs outside Parkinson's context. |
| ○ Traumatic Brain Injury | 4.5 | No direct TBI evidence. |
| ○ Libido / Sexual Health | 4.5 | No direct evidence. |
| ○ Fertility (Male) | 4.5 | No direct evidence. |
| ○ Fertility (Female) | 4.5 | No direct evidence. |
| ○ Skin / Beauty | 4.5 | Cutaneous vasodilation is acute, not durable. Some skin-tightening marketing claims lack evidence. |
| ○ Gut Health / Microbiome | 4.5 | No direct gut evidence. |
| ○ Kidney Function | 4.5 | No direct evidence. |
| ○ Sleep Architecture (Deep/REM) | 4.0 | No direct evidence. |
| ○ Circadian Rhythm / Chronobiology | 4.0 | No direct evidence. |
| ○ Cellular Senescence | 4.0 | No direct senescence evidence. |
| ○ Telomere / DNA Repair | 4.0 | No direct evidence. |
| ○ Methylation Support | 4.0 | No direct evidence. |
| ○ Heavy Metal / Toxin Burden | 4.0 | No direct evidence. |
| ○ Memory | 4.0 | No direct evidence. |
| ○ Flow State / Peak Mental Performance | 4.0 | No direct evidence. |
| ○ Creativity / Divergent Thinking | 4.0 | No direct evidence. |
| ○ Social Bonding / Empathy | 4.0 | Not applicable. |
| ○ Spiritual / Consciousness Expansion | 4.0 | Not applicable. |
| ○ Hair / Nail Health | 4.0 | No evidence. |
| ○ Eye / Vision Health | 4.0 | Ocular injury risk at high magnitudes (>7g) noted in literature; therapeutic ranges safe. |
| ○ Hearing / Auditory | 4.0 | No evidence. |
| ○ Dental / Oral Health | 4.0 | No evidence. |
| ○ Electromagnetic / Frequency Therapy | 4.0 | Not applicable — mechanical, not EMF. |
| ○ Cold / Heat Tolerance / Hormesis | 4.0 | Not applicable. |
Frequently Asked Questions
What is the difference between LMHF and pivotal whole body vibration platforms?
Low-Magnitude High-Frequency (LMHF) platforms like the Marodyne LivMD and Juvent run 30-90 Hz at ≤0.5g — designed for osteocyte signaling and bone density per Clinton Rubin's Stony Brook research. Pivotal or tri-planar platforms (Power Plate, Hypervibe) run 5-30 Hz at 1-3g+ — these trigger the tonic vibration reflex for muscle and performance. Pooling data across both produces heterogeneous, misleading meta-analyses.
Does whole body vibration actually improve bone density?
Yes, modestly, in the right populations on the right device. Fratini 2016 meta-analysis found Hedges g 0.09-0.21 BMD gains at lumbar spine and hip across postmenopausal and osteopenic women on LMHF platforms; Marin-Cascales 2018 confirmed similar hip BMD magnitude. Responders skew toward lowest-baseline BMD and highest adherence; higher-functioning postmenopausal women often show null results (Leung 2014).
Is whole body vibration safe?
Safe within therapeutic protocols (10-20 min/day standing, platform matched to indication). VIBES 24-month RCT (n=710) documented zero attributable adverse events. Most common side effect is cutaneous itch and erythema in ~22% (Mueller 2019), strongly platform-dependent. Absolute contraindications: pregnancy, active DVT, vibratory urticaria (ADGRE2 variant), acute fracture. Occupational 8-hour seated WBV exposure data does not apply to therapeutic standing use.
What are the contraindications for whole body vibration?
Absolute: pregnancy, active deep vein thrombosis, vibratory urticaria (ADGRE2 gene variant per Boyden 2016 NEJM), acute fracture. Relative: pacemaker or ICD (pivotal platforms create lead-site artifact), severe osteoporosis with vertebral compression history (for high-magnitude pivotal), recent lumbar disc surgery, retinal detachment. LMHF at ≤0.5g is materially safer than pivotal at 1-3g for spine and eye risk.
Does whole body vibration help Parkinson's disease?
Yes, as an adjunct. Marconi 2019 meta-analysis reported SMD 0.06-0.46 on motor outcomes with wide confidence intervals; UPDRS-III improvements cluster in the 3-6 point range, at or near the minimal clinically important difference. Protocol: 6-25 Hz, low amplitude, 5-10 min, 2-3x/week, supervised with PT initially to observe freezing-of-gait response.
How much does a whole body vibration platform cost?
Therapeutic-grade home units run $3,000-6,000 (Power Plate Move, Marodyne LivMD, Juvent). Budget Amazon platforms at $200-600 exist but often have frequency drift under load — the nominal 30 Hz setting can drop into 5 Hz lumbar-resonance bands, which is the most credible real-world safety concern in the consumer segment. Not all platforms that look the same are equivalent.
Can whole body vibration help low back pain?
Yes. Pooled SMD ~−0.6 for pain intensity across roughly 14 RCTs in chronic non-specific low back pain (del Pozo-Cruz 2012 meta and subsequent work). Effect size is moderate to large. One of the better-supported clinical indications. Caveat: acute disc pathology and recent spine surgery are contraindications; informed PT supervision is appropriate for chronic LBP with imaging findings.
Can I combine whole body vibration with blood flow restriction training?
Yes, and this is the biohacker strength stack (Greenfield-led). Pivotal WBV at 35-40 Hz provides the tonic vibration reflex stimulus while BFR cuffs at 40-50% arterial occlusion pressure restrict venous return, amplifying motor unit recruitment. Time-matched, it compresses a longer resistance session into 15-20 minutes. No head-to-head RCT yet compares this stack against conventional lifting.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New score |
|---|---|---|
| Mortality or fracture-rate RCT in osteopenic postmenopausal women confirms surrogate BMD signal | Efficacy 3.0→4.0, Evidence 3.5→4.3 | 8.2 / 10 (✅ Top-tier) |
| Cochrane-grade pooled analysis fully nulls LMHF BMD signal | Efficacy 3.0→2.0, Evidence 3.5→3.0 | 6.2 / 10 (👍 Worth trying, borderline) |
| Sub-$500 consumer platform validated for frequency stability under load | Cost 3.5→2.0 | 7.6 / 10 (💪 Strong recommend) |
| Parkinson's Phase 3 RCT lands SMD 0.6+ on UPDRS-III with durable 6-month follow-up | Efficacy 3.0→3.5, Breadth 4.0→4.3, Evidence 3.5→3.8 | 7.8 / 10 (💪 Strong recommend) |
| Case series documents vertebral compression in users with undiagnosed osteoporosis on pivotal platforms | Safety 1.8→2.8 | 6.8 / 10 (👍 Worth trying) |
| Head-to-head RCT: WBV + BFR stack beats conventional lifting on hypertrophy/strength per training-time unit | Efficacy 3.0→3.5, Breadth 4.0→4.3 | 7.6 / 10 (💪 Strong recommend) |
Key Evidence Sources
- Fratini A, et al. 2016. Whole body vibration treatments in postmenopausal women. Clin Interv Aging. Meta-analysis: Hedges g 0.09-0.21 BMD improvement at lumbar spine and hip. — Key LMHF BMD meta across postmenopausal and osteopenic populations.
- Marin-Cascales E, et al. 2018. Whole-body vibration training and bone health in postmenopausal women: a systematic review and meta-analysis. Medicine (Baltimore) 97(34):e11918. — Confirms hip BMD signal magnitude.
- Oliveira LC, et al. 2016. Effects of whole body vibration on muscle strength, bone mineral density, and gait speed in elderly people. A systematic review and meta-analysis. J Am Med Dir Assoc. — Frail and pre-frail populations; strength, function, Timed Up and Go improvements.
- Rogan S, et al. 2017. Effects of whole-body vibration on postural control in elderly: an update of a systematic review and meta-analysis. J Musculoskelet Neuronal Interact 17(1):16-21. — Sarcopenia effect on strength and function.
- Marconi NF, et al. 2019. Effects of whole-body vibration on Parkinson's disease: a systematic review and meta-analysis. Rehabil Res Pract. — Parkinson's motor outcomes, SMD 0.06-0.46; UPDRS-III 3-6 point range.
- Slatkovska L, et al. 2011. Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women: a randomized trial (VIBES). Ann Intern Med 155(10):668-79. — Landmark 24-month n=710 LMHF RCT; documented safety profile and BMD trends.
- Leung KS, et al. 2014. Effects of 18-month low-magnitude high-frequency vibration on fall rate and fracture risks in 710 community elderly women: a cluster-randomized controlled trial. Osteoporos Int. — Null result in higher-functioning postmenopausal women; informs responder phenotype argument.
- Mueller SM, et al. 2019. Cutaneous side effects of whole body vibration training: a comparative cohort study. Exp Dermatol 28(11):1233-1237. — Itch/erythema 22% pooled; 31.4% on side-alternating platforms, 0% on tri-planar.
- Boyden SE, et al. 2016. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med 374(7):656-63. — Genetic basis for vibratory urticaria; reproducible absolute contraindication.
- Rubin C, et al. 2001-present. Stony Brook mechanotransduction research. Multiple publications on LMHF osteocyte signaling, sclerostin suppression, osteoblast anabolism. — Foundational mechanism research for LMHF bone protocols; underpins Marodyne and Juvent regulatory clearances.
- del Pozo-Cruz B, et al. 2012. Effects of whole body vibration therapy on main outcome measures for chronic non-specific low back pain: a meta-analysis. Eur Spine J. — Low back pain pooled SMD ~−0.6; one of the stronger clinical indications.
- Prisby RD, et al. 2008. Effects of whole body vibration on the skeleton and other organ systems in man and animal models: what we know and what we need to know. Ageing Res Rev 7(4):319-29. — Organ-system-level review; frames what WBV does and does not do.
Other interventions for Geriatric
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.330 − 0.710 = 1.620
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.620 + 7) / 12) × 10 = 7.2 / 10
Further reading
7+ Best Whole Body Vibration Plates & Machines 2026 Review
Vibration therapy is a safe, semi-passive option for those who want to recover faster, to activate more muscles while exercising, naturally detox, build bone…
The Shortcut to Upgrade Your Endurance, Strength, VO2 Max & More (Used By Top NFL Players)
In this episode, I sit down with human performance expert Scott Hopson to explore the multifaceted benefits of WBV. From boosting mobility, flexibility, &…
